Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

COSM

Cosmos Health Inc

May 22 • 04:00PM ET

0.2525

-0.0028 -1.10 %

Healthcare • Medical Distribution • Greece • Nano • NASD

May 21, 2:30 PMCosmos Health posts record Q1 revenue as 4.87M Series B warrants expire unexercised, eliminating overhang with no dilution

Peers: HSIC CAH COR MCK TNXP

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.65	Insider Own	44.59%	Shs Outstand	41.07M	Perf Week	-16.28%
Market Cap	13.74M	Forward P/E	3.61	EPS next Y	0.07	Insider Trans	11.95%	Shs Float	30.16M	Perf Month	-29.27%
Enterprise Value	30.03M	PEG	-	EPS next Q	0.01	Inst Own	2.90%	Short Float	2.06%	Perf Quarter	-32.97%
Income	-21.13M	P/S	0.20	EPS this Y	101.59%	Inst Trans	0.41%	Short Ratio	0.68	Perf Half Y	-61.11%
Sales	69.49M	P/B	0.52	EPS next Y	600.00%	ROA	-35.35%	Short Interest	0.62M	Perf YTD	-49.30%
Book/sh	0.48	P/C	6.27	EPS next 5Y	-	ROE	-92.33%	52W High	1.32 -80.87%	Perf Year	-42.98%
Cash/sh	0.04	P/FCF	-	EPS past 3/5Y	73.29% -	ROIC	-80.00%	52W Low	0.25 2.48%	Perf 3Y	-92.53%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	9.04% 3.33%	Gross Margin	8.39%	Volatility	7.80% 7.52%	Perf 5Y	-99.83%
Dividend TTM	-	EV/Sales	0.43	EPS Y/Y TTM	37.35%	Oper. Margin	-25.75%	ATR (14)	0.03	Perf 10Y	-99.85%
Dividend Ex-Date	-	Quick Ratio	0.92	Sales Y/Y TTM	29.75%	Profit Margin	-30.41%	RSI (14)	26.84	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.08	EPS Q/Q	-89.81%	SMA20	-22.03%	Beta	4.21	Target Price	4.50
Payout	-	Debt/Eq	0.93	Sales Q/Q	30.74%	SMA50	-24.16%	Rel Volume	0.44	Prev Close	0.26
Employees	163	LT Debt/Eq	0.33	Earnings	May 21 BMO	SMA200	-57.42%	Avg Volume	910.99K	Price	0.25
IPO	Jul 23, 2010	Option/Short	Yes / Yes	EPS/Sales Surpr.	0.00% 0.00%	Trades		Volume	401,776	Change	-1.10%

May-21-26 02:20PM	Cosmos Health Announces Expiration of 4,874,126 Series B Warrants Unexercised; ~38% of Total Outstanding Warrants (ACCESSWIRE) -10.20%
09:15AM	Cosmos Health Reports Q1 2026 Results: Revenue Up 31% to $17.9M, New Q1 Record; Total Liabilities Reduced by $4.5M; Stockholders' Equity Up 7.6%; Cash of $2.2M; Record Momentum Continues into Q2 with U.S. Expansion Underway (ACCESSWIRE)
May-14-26 09:00AM	Cosmos Health, through its Subsidiary Cana Laboratories, Enters into an Advisory Agreement with the European Investment Bank (EIB) for the Financing of its 50M R&D Program; EIB Financing Represents up to 50%, or 25M, under the EIB's Venture Debt Program (ACCESSWIRE)
May-12-26 10:15AM	Cosmos Health Announces Withdrawal of Registration Statement on Form S-1 (ACCESSWIRE)
May-11-26 02:25PM	Cosmos Health Projects Over $3.2 Million in Incremental Annual Revenue from Fort18 in the United States Within 12-18 Months (ACCESSWIRE) -7.64%
11:25AM	Loading…
May-08-26 11:25AM	Cosmos Health Receives Updated Zacks Research Report: 2026 Revenue Forecast Raised to $103.2 Million, EPS Outlook Upgraded to Positive Territory, and $4.50 Valuation Reaffirmed (ACCESSWIRE) -5.06%
May-06-26 10:35AM	Cosmos Health Introduces Fort18 in the United States - A Men's Sexual Stamina Supplement Expanding the 18 Series into Men's Wellness (ACCESSWIRE)
Apr-30-26 12:50PM	Cosmos Health Projects Over $2.5 Million in Incremental Annual Revenue from Cur18 in the United States Within 12-18 Months (ACCESSWIRE)
Apr-21-26 12:50PM	Cosmos Health Introduces the "18 Series" in the United States - A Science-Driven Nutraceutical Platform Built on Patented Ingredients, Published Clinical Research, and Exact Clinical Dosing; Targeting a Portfolio of 18 Clinically Validated Products (ACCESSWIRE) -9.10%
Apr-20-26 10:55AM	Cosmos Health Accelerates U.S. Expansion: Liv18 Phase 1 Execution Complete; Production and Sales Commencing April 2026; Expected to Generate $5M+ in Annual Revenue at ~75% Gross Margins; Early U.S. Commercial Traction Observed Across Product Portfolio (ACCESSWIRE) -5.59%
Apr-17-26 02:00PM	Cosmos Health Continues US Expansion with Q2 Launch of Cur18 - a Clinically Studied, Patented Curcumin Next-Gen Therapy Supplement Delivering 39x Higher Bioavailability and Designed to Support Joint Health (ACCESSWIRE)
Apr-16-26 03:15PM	Cosmos Health Advances AI Investments to Enhance Efficiency, Reduce Costs, Improve Customer Experience and Drive Sales Growth; Certain Operating Expenses May Decrease by Up to 30% (ACCESSWIRE)
Apr-15-26 09:25AM	Cosmos Health Reports Full Year 2025 Results: Revenue Hits All-Time Record of $65.3M, Up 20%; Gross Profit Surges 83% to $7.9M; Gross Margin Expands 418 Basis Points; Adjusted EPS Improves 82%; Cash Position Up 10x to $3.5M; Record Growth Continues Into 2026 Across All Core Segments (ACCESSWIRE) +16.92%
Apr-13-26 12:50PM	Cosmos Health Receives Third Consecutive Purchase Order from Pharmalink for 60,000 Units of Sky Premium Life Products in the UAE; Cumulative Orders Reach 270,000 Units, Advancing 5-Year Goal of Over 3 million Units (ACCESSWIRE) +8.50%
Apr-10-26 09:40AM	Cosmos Health Reports No Impact from Iran and Middle East Conflict; Revenue Continues at All-Time High Levels; NOOR U.S. Expansion on Track to Exceed $12 Million Within 12 Months (ACCESSWIRE)
11:10AM	Loading…
Apr-08-26 11:10AM	Cosmos Health Continues Expansion in the United States with Q2 Launch of Liv18 - a Clinically Proven, Patented Supplement for Liver Fat Reduction (ACCESSWIRE)
Apr-01-26 11:42AM	Cosmos Health Announces Successful EN 12791 Study Results for C-Scrub Wash 4%, Strengthening Expansion into Hospital and Surgical Markets (ACCESSWIRE)
Mar-19-26 12:45PM	Cosmos Health Provides Update; Evaluates Options to Address Valuation Disconnect; Will Issue Updated Guidance Following FY 2025 Results; Record Growth Continues as Significant U.S. Expansion Underway, with Additional $12M+ in High-Margin Revenue Projected; Important R&D Updates Expected Following Finalization of Certain Anticipated Transactions (GlobeNewswire)
Mar-11-26 01:45PM	Cosmos Health Purchases $600,000 of Bitcoin, Expands Digital Asset Holdings to $3,100,000 (GlobeNewswire)
Mar-10-26 09:00AM	Cosmos Health Enters into LOI to Acquire $11,500,000 Pharmacy Distribution Network; Remains on Track to Deliver 2027 Revenue Guidance of $155,800,000 (GlobeNewswire) -6.02%
Feb-24-26 12:30PM	Cosmos Health Appoints Globally Recognized AI-Driven Drug Discovery and Clinical-Stage Biotech Expert Dr. Dimitrios Iliopoulos to Advisory Board (GlobeNewswire)
Feb-19-26 11:30AM	Cosmos Health Highlights Approximately $15 Million Fair Market Value of Real Estate Assets, Exceeding Current Market Capitalization; Evaluates Monetization Options to Address Significant Discount to Book Value (GlobeNewswire) -5.88%
Feb-18-26 01:45PM	Cosmos Health Continues UK Retail Expansion for C-Scrub; Now Available at Superdrug, the UK's Second-Largest Beauty and Health Retailer (GlobeNewswire) +9.53%
10:17AM	Cosmos Health Announces Growing Momentum for C-Scrub in the United Kingdom; Now Available at Tesco, the UK's Largest Retailer (GlobeNewswire)
Feb-17-26 11:25AM	Cosmos Health Showcases Expanding Brand Portfolio at World Health Expo Dubai 2026 (GlobeNewswire)
Feb-11-26 12:10PM	Cosmos Health Expands Digital Assets Program with $500,000 Bitcoin Purchase, Bringing Total Cryptocurrency Investments to $2.5 Million; Evaluates Inclusion of Other Select Cryptocurrencies (GlobeNewswire)
Jan-20-26 10:45AM	Cosmos Health Announces Accelerating Customer Growth, Improving Unit Economics and Robotic Expansion Supporting $40M in Additional Annual Revenue (GlobeNewswire) -5.57%
Jan-14-26 11:25AM	Cosmos Health Announces Initiation of Analyst Coverage with $4.50 Valuation by Zacks Small-Cap Research (GlobeNewswire)
Jan-05-26 09:30AM	Cosmos Health Enters Manufacturing Agreement with Libytec for PathMuscle Medicine, with Five-Year Volumes Expected to Exceed 1.2 Million Units (GlobeNewswire)
Dec-24-25 09:00AM	Cosmos Health Is Building a Platform, and Tariffs Are Accelerating the Strategy (ACCESSWIRE)
09:00AM	Loading…
Dec-19-25 09:00AM	Cosmos Health is Forcing the Market to Reframe the Conversation (ACCESSWIRE)
Dec-03-25 12:20PM	Cosmos Health Launches Strategic Partnership With Prime Ledger to Transform $300M Treasury and Tokenize IP Assets (GlobeNewswire) -10.81%
Dec-02-25 12:15PM	Cosmos Health CEO Greg Siokas Adds 3,398,055 Shares Year-to-Date 2025 Following Continued November Purchases (GlobeNewswire)
Nov-17-25 09:15AM	Cosmos Health Reports Record Q3 2025 Results with All-Time High Revenue, Gross Profit and Gross Margin; Revenue Up 38% to $17.1M, Gross Profit Up 116% to $2.6M, Adjusted EBITDA Up 74%, Cash Position Up to $4.63M from $0.66M (GlobeNewswire)
Oct-31-25 10:45AM	Cosmos Health Enters New Nanotechnology R&D Program to Develop Next-Generation Nutraceutical Formulas with Enhanced Phytochemical Efficacy (GlobeNewswire) -10.01%
Oct-21-25 12:10PM	Cosmos Health Expands Its Ethereum Holdings With an Additional $200,000 Purchase Under Its $300 Million Digital Assets Facility; Total Investment Now Reaches $2 Million (GlobeNewswire)
Oct-16-25 08:00AM	Cosmos Health Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire) -12.80%
Oct-13-25 02:05PM	Cosmos Health Purchases an Additional $300,000 in Ethereum Under Its $300 Million Digital Assets Facility; Total Investment Reaches $1.8 Million (GlobeNewswire)
Oct-10-25 08:00AM	Cosmos Health Purchases an Additional $500,000 in Ethereum Pursuant to its $300 Million Digital Assets Facility (GlobeNewswire)
Oct-03-25 03:56PM	Cosmos Health Expands Sky Premium Life Into $1Bn+ Kuwait Market; Signs Exclusive Distribution Agreement With Diyar United and Secures Initial Purchase Order of Over 65,000 Units (GlobeNewswire)
Sep-29-25 08:00AM	Cosmos Health CEO Issues Letter to Shareholders: Building a Global Healthcare Powerhouse with $300M Digital Financing Facility, U.S. Manufacturing Expansion, and AI Innovation (GlobeNewswire)
Sep-25-25 08:00AM	Cosmos Health Expands Order Book with Contract Manufacturing Agreement with Medical Pharmaquality S.A. for 3 Million MYCOFAGYL Pessaries Annually (GlobeNewswire)
Sep-22-25 08:00AM	Cosmos Health Commences U.S. Operations, Entering $164B Nutraceuticals Market with Its Sky Premium Life Brand; Expects 75% Gross Margins and Strong Cash Flow, with NOOR Collagen Alone Projected to Generate Over $12M in Annualized Revenue (GlobeNewswire) +15.39%
Sep-11-25 08:00AM	Cosmos Health Expands Presence in the $7 Billion GCC Nutraceuticals Market, Signs Distribution Agreement with Scientific Pharmacy for Sky Premium Life in Oman, Including Initial Purchase Order of 42,000 Units (GlobeNewswire) +10.51%
Aug-18-25 12:45PM	Cosmos Health Reports Q2 2025 Results; Continues Strong Growth with 11.7% Revenue Increase; On Track to Meet Profitability Targets with Gross Profit Up 53% to $3.21M in H1 2025 (GlobeNewswire) -5.27%
Aug-12-25 09:50AM	Cosmos Health Makes Initial $1M Ethereum Purchase Under Digital Asset Treasury Strategy (GlobeNewswire)
Aug-07-25 09:25AM	Cosmos Health secures $300M financing facility to launch Ethereum strategy (TipRanks) -8.70%
Aug-06-25 09:20AM	Cosmos Health Secures up to $300 Million Financing Facility to Launch Ethereum Treasury Strategy (GlobeNewswire) +30.98%
Jun-25-25 11:00AM	Cosmos Health enters U.S. market with DolCas Biotech agreement (TipRanks)
Jun-24-25 10:55AM	Cosmos Health Enters U.S. Market with Strategic Made-in-America Manufacturing, Mitigating Tariff Risks; Executes Agreement with New Jersey-Based DolCas Biotech (GlobeNewswire)
May-15-25 02:30PM	RETRANSMISSION - Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven (GlobeNewswire)
09:30AM	Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven (GlobeNewswire)
May-07-25 02:30PM	Cosmos Health Secures Follow-Up Order from Pharmalink for 80,000 Sky Premium Life Units in the UAE; Initial 130,000-unit Order Sold Out, Advancing 5-Year Goal of Over 3 Million Units (GlobeNewswire)
May-06-25 01:40PM	Cosmos Health Receives Additional 180-Day Compliance Period from Nasdaq (GlobeNewswire)
Apr-30-25 12:50PM	Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000 (GlobeNewswire)
Apr-16-25 12:45PM	Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million (GlobeNewswire)
Apr-09-25 01:40PM	Cosmos Health Further Expands Facility Upgrades Program at Cana Laboratories and Signs 5-Year Contract Manufacturing Agreement with Pharmex for 1.5 Million Bottles of the Antiseptic Drug AMBITASOL 1L (GlobeNewswire)
Apr-08-25 10:45AM	Cosmos Health Launches Sky Premium Life in Albania through Partnership with Pharma Cell; Secures Initial $300,000 Order (GlobeNewswire)
Feb-26-25 11:30AM	Cosmos Health Expands Sky Premium Life Nutraceuticals Brand with 60 New SKUs as Global Growth Accelerates (ACCESSWIRE)
Feb-18-25 08:30AM	Cosmos Health Announces It will not Proceed with an Offering Under Its Form S-1 (ACCESSWIRE)
Feb-11-25 10:15AM	Cosmos Health Enters Final Development Phase of CCX0722 Weight Management Solution; Expected Product Launch in Q1 or Q2 2026, Gaining Access to Over $142 Billion Market (ACCESSWIRE) -10.28%
Feb-10-25 01:30PM	Cosmos Health Advances Cancer Treatment Innovation with Two New AI-Driven Patent Filings for Gliomas and Hematologic Malignancies; $25 Billion+ Global Market (ACCESSWIRE)
09:45AM	Cosmos Health Strengthens Management Team with the Appointment of Veteran Executive Dimitris Moraitis as Vice President of Strategy & Operations (ACCESSWIRE)
Feb-07-25 10:00AM	Cosmos Health Secures 10-Year Long-Term Contract Manufacturing Order from Provident Pharmaceuticals for 4 Additional Products, Totaling 8 Million Packs, Significantly Expanding High-Margin Revenue Backlog and Cash Flow Visibility (ACCESSWIRE)
Feb-06-25 03:50PM	Cosmos Health Receives $578,460 Initial Purchase Order from Al Rabwa International for Sky Premium Life Food Supplements in Qatar (ACCESSWIRE)
Feb-05-25 11:05AM	Cosmos Health Files New AI-Driven Patent Application for Multiple Sclerosis Treatment, Targeting $25 Billion+ Global Market (ACCESSWIRE)
Jan-28-25 11:00AM	Cosmos Health Secures Bond Loan from European Bank on Very Competitive Terms, with Option to Upsize to Support Growth and Achieve Positive Operating Cash Flow (ACCESSWIRE) -11.39%
Jan-27-25 03:50PM	Cosmos Health Submits Patent Application for Allergic Inflammation Therapy by Leveraging AI Drug Repurposing; Allergy Treatment Market Valued at $23.5 Billion (ACCESSWIRE)
Jan-23-25 03:35PM	Cosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait (ACCESSWIRE)
Jan-22-25 08:00AM	Cosmos Health Secures Two WIPO-Patented Anticancer Drugs for Prostate, Ovarian, and Colorectal Cancers, Valued at Over $24.5 Million (ACCESSWIRE) -17.08%
Jan-21-25 03:00PM	Cosmos Health CEO Greg Siokas Acquires a Total of 647,809 Shares Valued at $425,000 Over the Past 32 Days (ACCESSWIRE) +8.47%
Jan-14-25 09:41AM	Cosmos Health secures exclusive distribution agreement with Virax Biolabs (TipRanks) +12.55%
Jan-13-25 09:20AM	Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries (ACCESSWIRE)
Dec-26-24 01:30PM	Cosmos Health Strengthens RandD Leadership and Innovation with the Appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology (ACCESSWIRE)
01:30PM	Cosmos Health Strengthens R&D Leadership and Innovation with the Appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology (ACCESSWIRE)
Dec-23-24 09:25AM	Cosmos Health CEO Greg Siokas and CFO George Terzis Collectively Increase Stake by 343,000 Shares Valued at $200,000 (ACCESSWIRE) +6.02%
Nov-26-24 09:30AM	Taglich Brothers Releases Updated Coverage on Cosmos Health: Projects Positive EPS for 2025 and Sets $3 Price Target, Nearly 300% Above Current Share Price (ACCESSWIRE)
Nov-18-24 08:00AM	Cosmos Health Integrates Bitcoin and Ethereum as Treasury Reserve Assets (ACCESSWIRE) +11.13%
Nov-15-24 10:20AM	Cosmos Health Reports Q3 2024 Results: Resilient Revenue and Gross Profit Amid 18.6% Expense Reduction; Stockholders' Equity Up 8.8% to $35M (ACCESSWIRE)
Nov-12-24 12:00PM	Cosmos Health Issues Letter to Shareholders (ACCESSWIRE) +7.09%
Nov-01-24 12:30PM	Cosmos Health's Subsidiary CosmoFarm Achieves Record Revenue, Up 8.62% to $43 Million YTD 2024, with Gross Profit Rising 21% (ACCESSWIRE) -5.32%
Sep-25-24 09:25AM	Cosmos Health Reports Strong 160% Increase in 2024 YTD Sales on Amazon UK for Its Proprietary Brands (ACCESSWIRE) -10.27%
Sep-23-24 12:55PM	Cosmos Health Receives Initial Orders Exceeding $500,000 for C-Scrub in the UK; Future Orders Booked at Accelerated Pace with Strong Profitability Anticipated Due to High Profit Margins (ACCESSWIRE) -8.18%
09:00AM	Cosmos Health Expands Global Presence into India, a Market with Over 1.4Bn People, Through Exclusive Agreement to Distribute Virax Biolabs' Mpox PCR Detection Kits (ACCESSWIRE)
Sep-19-24 03:40PM	Cosmos Health Enters Development Phase for CCDL24, an Innovative Multitargeting Product for Gastrointestinal Disorders, with a Market Size Valued at Over $37.5 Billion (ACCESSWIRE)
Sep-18-24 01:30PM	Cosmos Health Releases 2024-2027 Updated Guidance; Projects Revenue of $155.8M and Adjusted EBITDA of $29.4M Annually by 2027, Driven by Strategic Focus on High-Margin Segments (ACCESSWIRE)
Sep-17-24 11:45AM	Taglich Brothers Publishes Updated Coverage Report on Cosmos Health; Maintains Price Target of $4, Nearly 300% Above Current Share Price (ACCESSWIRE) +13.43%
Sep-16-24 08:30AM	Virax Biolabs Announces Extension of Existing Exclusive Distribution Agreement to Market Mpox (formerly Monkeypox) Virus Real-Time PCR Detection Kits with Cosmos Health Inc. (PR Newswire)
08:30AM	Cosmos Health Secures Exclusivity Agreement with Virax Biolabs to Distribute mpox PCR Kits across the GCC, including the UAE, Saudi Arabia, Bahrain, Kuwait, Oman, and Qatar (ACCESSWIRE)
Aug-23-24 09:35AM	Cosmos Health Regains Full Compliance with Nasdaq Listing Requirements (ACCESSWIRE)
Aug-21-24 10:20AM	Cosmos Health Holds EU Distribution Rights for Virax Biolabs' Mpox (formerly Monkeypox) Virus Real-Time PCR Detection Kits (ACCESSWIRE) +17.76%
Aug-20-24 12:20PM	Cosmos Health Reports Q2 2024 Results: Sustains Positive Momentum with 7% Revenue Growth vs. Q1 2023 and 12.5% vs. H1 2023 (ACCESSWIRE) -15.08%
09:00AM	Cosmos Health Reports Q1 2024 Results: Continues to Deliver Strong Growth and Improved Performance with 18% YoY Revenue Increase and 39% Rise in Gross Profit (ACCESSWIRE)
Aug-08-24 01:00PM	Cosmos Health Completes Registration Process in Germany to Commence Sales of its C-Scrub Antimicrobial Wash; Enters $750M+ Market (ACCESSWIRE)
Aug-06-24 09:00AM	Cosmos Health Reports Full Year 2023 Results: Revenue Increases to $53.4M, or 6% YoY; Stockholders' Equity Remains Near Record Highs at $36M, or $2.25 per Share (ACCESSWIRE) +15.00%
Jul-25-24 02:45PM	Cosmos Health Successfully Submits Tender for C-Scrub Wash Chlorhexidine 4% to Supply NHS Scotland (ACCESSWIRE) +5.79%
11:40AM	Cosmos Health Signs Distribution Agreement with ProMed Trading for Its Sky Premium Life Food Supplements in Qatar (ACCESSWIRE)
Jul-24-24 10:55AM	Cosmos Health Updates on Contract Manufacturing Division; Completes Phase I of Production Capacity Expansion, Positioned to Generate Over $10M in Annual Gross Profit at Full Capacity (ACCESSWIRE)
Jul-19-24 11:40AM	Cosmos Health Regains Compliance with Nasdaq Minimum Bid Price Rule (ACCESSWIRE)
Jul-18-24 03:45PM	Cosmos Health's Cana Secures Additional Contract Manufacturing Agreement with Provident Pharmaceuticals for 700,000 Units, Bringing Total Order Book to 5.02 Million Units (ACCESSWIRE) -10.36%

Cosmos Health, Inc. is a pharmaceutical company, which engages in the importation, exportation, distribution, and sale of pharmaceutical products. It is also involved in the research and development of its business units, and acquisition of pharmaceutical companies. The firm offers over-the-counter drugs, branded and generic medicines, and dietary and vitamin supplements. The company was founded on July 21, 2009 and is headquartered in Thessaloniki, Greece.

Chairman & CEOMr. Grigorios Siokas

Chief Financial OfficerMr. Georgios Terzis

Chief Operating OfficerMr. Nikolaos Bardakis

Secretary & Independent DirectorMr. Demetrios G. Demetriades

Head of OncologyProf. Dimitrios Trafalis

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Siokas Grigorios	Chief Executive Officer	Feb 12 '26	Buy	0.37	388,532	145,000	8,861,914	Feb 13 10:05 AM
Siokas Grigorios	Chief Executive Officer	Feb 11 '26	Buy	0.41	291,262	120,000	8,473,382	Feb 12 02:20 PM
Siokas Grigorios	Chief Executive Officer	Jan 23 '26	Buy	0.50	90,325	45,000	8,182,120	Jan 26 11:48 AM
Siokas Grigorios	Chief Executive Officer	Jan 20 '26	Buy	0.50	353,321	175,000	8,091,795	Jan 21 10:11 AM
Siokas Grigorios	Chief Executive Officer	Jan 14 '26	Buy	0.45	493,495	220,000	7,738,474	Jan 15 09:40 AM
Siokas Grigorios	Chief Executive Officer	Jan 12 '26	Buy	0.50	113,185	57,000	7,244,979	Jan 13 10:00 AM
Siokas Grigorios	Chief Executive Officer	Jan 08 '26	Buy	0.52	156,190	81,000	7,131,794	Jan 09 11:43 AM
Siokas Grigorios	Chief Executive Officer	Jan 07 '26	Buy	0.52	124,880	65,000	6,975,604	Jan 08 10:41 AM
Siokas Grigorios	Chief Executive Officer	Jan 06 '26	Buy	0.54	133,953	72,000	6,850,724	Jan 07 01:01 PM
Siokas Grigorios	Chief Executive Officer	Dec 19 '25	Buy	0.49	88,314	43,000	6,716,771	Dec 22 10:45 AM
Siokas Grigorios	Chief Executive Officer	Dec 15 '25	Buy	0.42	168,472	70,000	6,628,457	Dec 16 12:17 PM
Siokas Grigorios	Chief Executive Officer	Nov 28 '25	Buy	0.64	76,360	49,000	6,459,985	Dec 01 12:02 PM
Siokas Grigorios	Chief Executive Officer	Nov 25 '25	Buy	0.63	55,732	35,000	6,383,625	Nov 26 12:52 PM
Siokas Grigorios	Chief Executive Officer	Nov 21 '25	Buy	0.68	56,080	38,000	6,327,893	Nov 24 02:47 PM
Siokas Grigorios	Chief Executive Officer	Nov 20 '25	Buy	0.62	51,315	32,000	6,271,813	Nov 21 10:07 AM
Siokas Grigorios	Chief Executive Officer	Nov 19 '25	Buy	0.65	61,614	40,000	6,220,498	Nov 20 11:06 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

COSM

Cosmos Health Inc

Upgrade your Finviz experience